Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.69 |
| ▸ | HTR2A | P28223 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065053 | 0.84 | SLC6A4 (0.69) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL5878711 | 0.81 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A3SLC6A2 | |
| SCHEMBL7213331 | 0.74 | SLC6A4 (0.54) | SLC6A4HTR2AKCNH2SLC6A3SLC6A2 | |
| SCHEMBL7206520 | 0.73 | SLC6A4 (0.56) | SLC6A4HTR2AKCNH2SLC6A3SLC6A2 | |
| SCHEMBL7207921 | 0.73 | SLC6A4 (0.53) | SLC6A4HTR2AKCNH2SOS1SLC6A3 | |
| SCHEMBL7207929 | 0.73 | SLC6A4 (0.53) | SLC6A4HTR2AKCNH2SOS1SLC6A3 | |
| SCHEMBL5837285 | 0.73 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SOS1SLC6A3 | |
| SCHEMBL5878837 | 0.72 | SLC6A4 (0.83) | SLC6A4HTR2AKCNH2SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL5837785 | 0.72 | SLC6A4 (0.97) | SLC6A4HTR2AKCNH2SOS1SLC6A3 | |
| SCHEMBL7207176 | 0.71 | SLC6A4 (0.53) | SLC6A4HTR2AKCNH2SOS1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |